Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
Status:
Completed
Trial end date:
2021-02-11
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of sirolimus
or vorinostat that can be given in combination with hydroxychloroquine to patients with
advanced cancer. The safety of these drug combinations will also be studied.